Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective

PharmacoEconomics
Jonathan KarnonPaul E Goss

Abstract

MA17 was a randomised placebo-controlled trial of letrozole 2.5 mg/day in 5187 estrogen receptor-positive, 50% node-negative, postmenopausal women (median age 62 years at enrollment) with early breast cancer, post-5 years' adjuvant tamoxifen therapy. The objective of this evaluation was to extrapolate the findings from the MA17 trial to estimate the lifetime cost effectiveness of letrozole in this setting. A Markov model was used to estimate the incremental cost per QALY gained with extended adjuvant letrozole versus no therapy. Probabilities of disease progression and death were estimated using data from the MA17 study and other secondary sources. Costs of breast cancer care (letrozole therapy, surveillance, recurrences, terminal care) and treatment of osteoporosis and utilities were derived from literature. A full probabilistic sensitivity analysis was undertaken. The analysis was conducted from the perspective of the UK National Health Service (NHS) and cost estimates reflect 2004 values. All costs and outcomes were discounted at 3.5%. Extended adjuvant letrozole resulted in a gain of 0.36 QALYs per patient (13.66 vs 13.30 with no therapy). These benefits were obtained at an additional expected lifetime cost of 3732 pounds p...Continue Reading

References

Jan 1, 1983·International Journal of Radiation Oncology, Biology, Physics·L M ToonkelC B Wallach
Oct 1, 1993·Medical Decision Making : an International Journal of the Society for Medical Decision Making·F A Sonnenberg, J R Beck
Oct 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T SaphnerR Gray
May 7, 1999·Medical Decision Making : an International Journal of the Society for Medical Decision Making·S E GabrielA N Tosteson
Feb 8, 2000·International Journal of Radiation Oncology, Biology, Physics·B J HaylockK S Wilson
Apr 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C SchmoorM Schumacher
Mar 19, 2002·The Breast Journal·Meena S Moran, Bruce G Haffty
Mar 26, 2003·Health Technology Assessment : HTA·J A KanisM Lloyd Jones

❮ Previous
Next ❯

Citations

Jan 18, 2007·Journal of Cancer Research and Clinical Oncology·Fritz Jänicke
Oct 17, 2007·Journal of Cancer Research and Clinical Oncology·Carsten Rose
Jul 6, 2006·Breast Cancer Research and Treatment·Khalid El OuagariJane Brandman
Mar 31, 2010·Breast Cancer Research and Treatment·Sekwon JangNavneet S Majhail
Apr 1, 2007·Expert Review of Pharmacoeconomics & Outcomes Research·Jonathan Karnon
Jun 10, 2006·Expert Review of Anticancer Therapy·J Michael Dixon
Aug 10, 2007·Expert Opinion on Pharmacotherapy·Lesley-Ann N MillerGerald M Higa
Aug 19, 2007·Expert Opinion on Pharmacotherapy·Surabhi AmarEdith A Perez
Sep 2, 2008·Expert Opinion on Drug Safety·Sundus Ozair, Shabana Iqbal
Oct 29, 2008·Current Medical Research and Opinion·N Harbeck
Nov 3, 2012·Critical Reviews in Oncology/hematology·Michaela J HigginsPaul E Goss
Dec 17, 2008·Clinical Breast Cancer·Mary Cianfrocca
Nov 17, 2007·Cancer Treatment Reviews·David Dodwell, Debbie Williamson
Jul 3, 2007·The Journal of Steroid Biochemistry and Molecular Biology·Per E Lønning, Jürgen Geisler
Jun 5, 2007·The Breast : Official Journal of the European Society of Mastology·K Gelmon
Jan 24, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Gerardus W J FrederixJan H M Schellens
Aug 31, 2016·Breast Cancer Research and Treatment·Virginie NerichBernhard Holzner
Nov 26, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rachel J D CossettiKaren A Gelmon
Sep 1, 2007·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Jonathan KarnonRon Akehurst
May 12, 2007·International Journal of Technology Assessment in Health Care·Mathias LidgrenClas Rehnberg
May 19, 2006·PharmacoEconomics·Christopher Dunn, Susan J Keam
Jul 29, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T E DeleaP E Goss

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.